241 related articles for article (PubMed ID: 11127947)
21. Tumor targeting by conjugation of DHA to paclitaxel.
Bradley MO; Swindell CS; Anthony FH; Witman PA; Devanesan P; Webb NL; Baker SD; Wolff AC; Donehower RC
J Control Release; 2001 Jul; 74(1-3):233-6. PubMed ID: 11489499
[TBL] [Abstract][Full Text] [Related]
22. The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study.
Lesser GJ; Grossman SA; Eller S; Rowinsky EK
Cancer Chemother Pharmacol; 1995; 37(1-2):173-8. PubMed ID: 7497589
[TBL] [Abstract][Full Text] [Related]
23. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract][Full Text] [Related]
24. Conjugation of camptothecins to poly-(L-glutamic acid).
Singer JW; De Vries P; Bhatt R; Tulinsky J; Klein P; Li C; Milas L; Lewis RA; Wallace S
Ann N Y Acad Sci; 2000; 922():136-50. PubMed ID: 11193889
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors.
Li C; Yu DF; Inoue T; Yang DJ; Tansey W; Liu CW; Milas L; Hunter NR; Kim EE; Wallace S
J Nucl Med; 1997 Jul; 38(7):1042-7. PubMed ID: 9225788
[TBL] [Abstract][Full Text] [Related]
26. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Egorin MJ; Zuhowski EG; Sentz DL; Dobson JM; Callery PS; Eiseman JL
Cancer Chemother Pharmacol; 1999; 44(4):283-94. PubMed ID: 10447575
[TBL] [Abstract][Full Text] [Related]
27. Preclinical antitumor activity of water-soluble paclitaxel derivatives.
Rose WC; Clark JL; Lee FY; Casazza AM
Cancer Chemother Pharmacol; 1997; 39(6):486-92. PubMed ID: 9118459
[TBL] [Abstract][Full Text] [Related]
28. [Feasibility, activity, and change in the level of blood paclitaxel concentration after weekly paclitaxel therapy for a patient with recurrent ovarian cancer].
Ishioka S; Sagae S; Kudo R
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1017-21. PubMed ID: 11478132
[TBL] [Abstract][Full Text] [Related]
29. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
30. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
31. Determinants of paclitaxel penetration and accumulation in human solid tumor.
Kuh HJ; Jang SH; Wientjes MG; Weaver JR; Au JL
J Pharmacol Exp Ther; 1999 Aug; 290(2):871-80. PubMed ID: 10411604
[TBL] [Abstract][Full Text] [Related]
32. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel.
Schimming R; Mason KA; Hunter N; Weil M; Kishi K; Milas L
Cancer Chemother Pharmacol; 1999; 43(2):165-72. PubMed ID: 9923824
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
[TBL] [Abstract][Full Text] [Related]
34. Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.
Masunaga SI; Ono K; Suzuki M; Nishimura Y; Kinashi Y; Takagaki M; Hori H; Nagasawa H; Uto Y; Tsuchiya I; Sadahiro S; Murayama C
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):1063-72. PubMed ID: 11429234
[TBL] [Abstract][Full Text] [Related]
35. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment.
Knemeyer I; Wientjes MG; Au JL
Cancer Chemother Pharmacol; 1999; 44(3):241-8. PubMed ID: 10453726
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin.
Colombo T; Parisi I; Zucchetti M; Sessa C; Goldhirsch A; D'Incalci M
Ann Oncol; 1999 Apr; 10(4):391-5. PubMed ID: 10370780
[TBL] [Abstract][Full Text] [Related]
37. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo.
Singer JW; Bhatt R; Tulinsky J; Buhler KR; Heasley E; Klein P; de Vries P
J Control Release; 2001 Jul; 74(1-3):243-7. PubMed ID: 11489501
[TBL] [Abstract][Full Text] [Related]
38. Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies.
Ahmed AE; Jacob S; Giovanella BC; Kozielski AJ; Stehlin JS; Liehr JG
Cancer Chemother Pharmacol; 1996; 39(1-2):122-30. PubMed ID: 8995509
[TBL] [Abstract][Full Text] [Related]
39. Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel.
Yamada H; Uchida N; Maekawa R; Yoshioka T
Cancer Lett; 2001 Oct; 172(1):17-25. PubMed ID: 11595125
[TBL] [Abstract][Full Text] [Related]
40. Tissue distribution, metabolism and excretion of paclitaxel in mice.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Anticancer Drugs; 1996 Jan; 7(1):78-86. PubMed ID: 8742102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
